Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


10.07.2017

1 Abdom Radiol (NY)
1 Anticancer Res
1 Arch Ital Urol Androl
1 BMC Cancer
1 Br J Cancer
1 Cancer Chemother Pharmacol
1 Chem Biol Drug Des
1 Drugs
1 Eur J Cancer Prev
1 Food Nutr Res
1 Fukushima J Med Sci
1 Int Urol Nephrol
1 Intern Med J
1 Med Hypotheses
1 Mol Biosyst
1 Nat Rev Urol
1 Oncol Rep
2 Oncotarget


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Abdom Radiol (NY)

  1. TRINH TW, Glazer DI, Sadow CA, Sahni VA, et al
    Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results.
    Abdom Radiol (NY). 2017 Jul 4. doi: 10.1007/s00261-017-1249.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients.
    Anticancer Res. 2017;37:3537-3541.
    PubMed     Text format     Abstract available


    Arch Ital Urol Androl

  3. GOZEN AS, Umari P, Scheitlin W, Su FE, et al
    Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Arch Ital Urol Androl. 2017;89:102-105.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. DESCOTES F, Kara N, Decaussin-Petrucci M, Piaton E, et al
    Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  6. MBATCHI LC, Gassiot M, Pourquier P, Goberna A, et al
    Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
    Cancer Chemother Pharmacol. 2017 Jul 4. doi: 10.1007/s00280-017-3379.
    PubMed     Text format     Abstract available


    Chem Biol Drug Des

  7. KE K, Li H, Yao H, Shi XN, et al
    In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
    Chem Biol Drug Des. 2017;89:505-513.
    PubMed     Text format     Abstract available


    Drugs

  8. FARINA MS, Lundgren KT, Bellmunt J
    Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Drugs. 2017;77:1077-1089.
    PubMed     Text format     Abstract available


    Eur J Cancer Prev

  9. VAN OSCH FHM, Pauwels CGGM, Jochems SHJ, Fayokun R, et al
    Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer.
    Eur J Cancer Prev. 2017 Jul 4. doi: 10.1097/CEJ.0000000000000404.
    PubMed     Text format     Abstract available


    Food Nutr Res

  10. SHIN SS, Song JH, Hwang B, Park SL, et al
    Angiopoietin-like protein 4 potentiates DATS-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; involvement of G2/M-phase cell cycle arrest, signaling pathways, and transcription factors-mediated MMP-9 expression.
    Food Nutr Res. 2017;61:1338918.
    PubMed     Text format     Abstract available


    Fukushima J Med Sci

  11. KIKUCHI K, Shigihara T, Hashimoto Y, Miyajima M, et al
    Apparent diffusion coefficient on magnetic resonance imaging (MRI) in bladder cancer: relations with recurrence/progression risk.
    Fukushima J Med Sci. 2017 Jul 5. doi: 10.5387/fms.2017.
    PubMed     Text format     Abstract available


    Int Urol Nephrol

  12. VAN DE PUTTE EEF, Vegt E, Mertens LS, Bruining A, et al
    FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
    Int Urol Nephrol. 2017 Jul 3. doi: 10.1007/s11255-017-1637.
    PubMed     Text format     Abstract available


    Intern Med J

  13. ROBINSON ARL, Radhakrishnan R, Horvath R, Pandey S, et al
    A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guerin therapy for superficial urinary bladder cancer.
    Intern Med J. 2017;47:820-823.
    PubMed     Text format     Abstract available


    Med Hypotheses

  14. DAVIS RL 3RD, Le W, Cui Z
    Granulocytes as an effector mechanism of BCG therapy for bladder cancer.
    Med Hypotheses. 2017;104:166-169.
    PubMed     Text format     Abstract available


    Mol Biosyst

  15. CHEN Y, Xie H, Zou Y, Lai X, et al
    Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.
    Mol Biosyst. 2017 Jul 3. doi: 10.1039/c7mb00202.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  16. LOBO N, Mount C, Omar K, Nair R, et al
    Landmarks in the treatment of muscle-invasive bladder cancer.
    Nat Rev Urol. 2017 Jul 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  17. WANG S, Liu B, Zhang J, Sun W, et al
    Centromere protein U is a potential target for gene therapy of human bladder cancer.
    Oncol Rep. 2017 Jun 30. doi: 10.3892/or.2017.5769.
    PubMed     Text format     Abstract available


    Oncotarget

  18. LIU Q, Diao R, Feng G, Mu X, et al
    Risk score based on three mRNA expression predicts the survival of bladder cancer.
    Oncotarget. 2017 Jun 27. doi: 10.18632/oncotarget.18642.
    PubMed     Text format     Abstract available

  19. BI H, Zhang Z, Guo L, Fu C, et al
    Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.
    Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18791.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: